๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 7 Shanghai 6 Guangzhou 5 Hangzhou 4 Chengdu 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing7 Shanghai6 Guangzhou5 Hangzhou4 Chengdu3
All 18 locations
Target enrolment
to

Trials with a site in Beijing

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905Chronic Spontaneous Urticaria
DrugBBT001
Bambusa Therapeutics
Phase 1/2
48
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jinzhou, Wuxi, Taiyuan, Xiโ€™an
2026-06-29
Recruiting
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
NCT07402213Chronic Spontaneous Urticaria
Jemincare
Phase 3
240
Beijing
2026-03-09
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Trial of JYB1904 in Chronic Spontaneous Urticaria.
NCT06509334Chronic Spontaneous Urticaria
Jemincare
Phase 2
135
Beijing
2024-08-04
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

5 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 7 studies
PhaseStudiesRecruitingShare
Phase 33142.9%
Phase 22228.6%
Phase 11114.3%
Phase 1/21114.3%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Jemincare22
Novartis Pharmaceuticals20
Bambusa Therapeutics11
BeOne Medicines11
Pfizer11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.